FY2026 EPS Forecast for Theratechnologies Lowered by Analyst

Theratechnologies Inc. (NASDAQ:THTX - Free Report) - Equities researchers at Leede Financial cut their FY2026 earnings per share (EPS) estimates for Theratechnologies in a research note issued to investors on Monday, April 14th. Leede Financial analyst D. Loe now forecasts that the company will earn $0.12 per share for the year, down from their previous forecast of $0.15. The consensus estimate for Theratechnologies' current full-year earnings is $0.01 per share. Leede Financial also issued estimates for Theratechnologies' FY2027 earnings at $0.20 EPS.

A number of other research analysts have also weighed in on the company. Jones Trading upgraded Theratechnologies from a "hold" rating to a "strong-buy" rating in a research report on Friday, April 11th. Research Capitl raised shares of Theratechnologies to a "strong-buy" rating in a report on Friday, February 14th.

Theratechnologies Trading Down 1.9 %

Shares of THTX stock traded down $0.05 during mid-day trading on Tuesday, reaching $2.52. The stock had a trading volume of 758,784 shares, compared to its average volume of 770,955. Theratechnologies has a 52-week low of $1.08 and a 52-week high of $3.13. The firm has a market capitalization of $115.87 million, a PE ratio of -25.20 and a beta of 1.11. The stock's 50-day moving average price is $1.69 and its two-hundred day moving average price is $1.55.

Hedge Funds Weigh In On Theratechnologies

Institutional investors have recently added to or reduced their stakes in the business. Harbour Investments Inc. grew its stake in shares of Theratechnologies by 20.0% in the fourth quarter. Harbour Investments Inc. now owns 87,772 shares of the company's stock worth $159,000 after purchasing an additional 14,655 shares in the last quarter. Raymond James Financial Inc. bought a new position in Theratechnologies in the fourth quarter valued at about $27,000. Bank of America Corp DE raised its stake in Theratechnologies by 1,416.7% during the 4th quarter. Bank of America Corp DE now owns 16,487 shares of the company's stock worth $30,000 after buying an additional 15,400 shares during the period. JPMorgan Chase & Co. acquired a new position in Theratechnologies during the fourth quarter valued at approximately $33,000. Finally, Wealthspire Advisors LLC boosted its holdings in Theratechnologies by 39.0% in the 4th quarter. Wealthspire Advisors LLC now owns 71,250 shares of the company's stock valued at $129,000 after purchasing an additional 20,000 shares during the period.

About Theratechnologies

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.